All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IBI326
Therapeutic Area: Oncology Product Name: IBI326
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: IASO
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2021
Details:
The BTD designation for IBI326 is based on the results observed in ongoing Phase 1/2 study for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) being conducted in China.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ipilimumab,Sintilimab
Therapeutic Area: Oncology Product Name: IBI310
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2021
Details:
NCT04720716 is a randomized, open-label, controlled, multicenter phase III study evaluating the efficacy and safety of IBI310 in combination with TYVYT® (sintilimab injection) for advanced HCC patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bevacizumab
Therapeutic Area: Oncology Product Name: Byvasda
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Etana Biotechnologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 19, 2021
Details:
Etana is committed to launch BYVASDA® in the local market. In return, Innovent will receive milestones for development and commercialization as well as double-digit royalties on net sales.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sintilimab
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2021
Details:
This sNDA was based on a randomized, open-label, Phase 3 clinical trial (ORIENT-3)—evaluating TYVYT® (sintilimab injection) as second-line therapy for patients with advanced or recurrent sqNSCLC whose cancer had progressed on first-line platinum-based chemotherapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bevacizumab
Therapeutic Area: Oncology Product Name: Byvasda
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 28, 2020
Details:
BYVASDA® (bevacizumab biosimilar), a recombinant humanized anti-VEGF monoclonal antibody drug independently developed by Innovent, has been officially approved by the NMPA of China for the treatment of adult recurrent glioblastoma.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Adalimumab
Therapeutic Area: Dermatology Product Name: SULINNO
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2020
Details:
SULINNO, has been officially approved by the NMPA of China for two new indications, including the treatment of pediatric plaque psoriasis and non-infectious intermediate uveitis, posterior uveitis and panuveitis in adults who do not respond adequately to corticosteroids.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IBI310,Sintilimab
Therapeutic Area: Oncology Product Name: IBI310
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2020
Details:
The Phase 2 clinical trial will be evaluating the efficacy and safety of IBI310 versus placebo, in combination with TYVYT, for advanced cervical cancer patients who have failed first and later line or intolerant of platinum-based chemotherapy.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
